Voyager director granted 30,000 stock options
Voyager Therapeutics, Inc. director Michael J. Higgins received a grant of stock options covering 30,000 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Voyager Therapeutics, Inc. director Michael J. Higgins received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of 3.43 per share and expire on June 9, 2036.
The award was issued under Voyager’s 2025 Stock Incentive Plan as part of its director compensation policy. All 30,000 underlying shares vest on the earlier of one year from the grant date or the next annual stockholder meeting, if he continues serving as a director.
Insider Trade Summary
Grant/Award: 30,000 shares
Grant/Award
1 txn
Insider
Higgins Michael J
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 30,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 30,000 contracts (Direct)
Footnotes (1)
- F1. This stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director.
Key Figures
Options granted: 30,000 options
Exercise price: 3.43 per share
Expiration date: June 9, 2036
+1 more
4 metrics
Options granted
30,000 options
Stock option grant to director on June 9, 2026
Exercise price
3.43 per share
Exercise price for 30,000 option shares
Expiration date
June 9, 2036
Option expiration for 30,000 granted options
Total derivative holdings after grant
30,000 options
Total stock options held following this transaction
Key Terms
Stock Option (Right to Buy), 2025 Stock Incentive Plan, director compensation policy, vesting commencement date
4 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
2025 Stock Incentive Plan financial
"issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc."
director compensation policy financial
"in accordance with its director compensation policy"
vesting commencement date financial
"The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date."
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Michael J. Higgins report in this Voyager Therapeutics (VYGR) Form 4?
Michael J. Higgins reported receiving a stock option grant for 30,000 Voyager Therapeutics common shares. The award is a director compensation grant under the 2025 Stock Incentive Plan, not an open-market purchase, and is exercisable at 3.43 per share until June 9, 2036.
How many Voyager Therapeutics (VYGR) options did Michael J. Higgins receive and at what price?
He received options covering 30,000 shares of Voyager Therapeutics common stock at an exercise price of 3.43 per share. These options give him the right, but not the obligation, to buy those shares at that price before their June 9, 2036 expiration.
What is the vesting schedule for Michael J. Higgins’ Voyager Therapeutics (VYGR) option grant?
All 30,000 option shares vest in a single tranche on the earlier of one year from the grant date or the next annual stockholder meeting. Vesting is conditional on Michael J. Higgins continuing to serve as a director through the applicable vesting date.
Is Michael J. Higgins’ Voyager Therapeutics (VYGR) Form 4 transaction a stock purchase or a compensation grant?
The Form 4 shows a compensation grant, not a market purchase. Michael J. Higgins received 30,000 stock options for director service, with zero-cost grant on the transaction date and an exercise price of 3.43 per share, issued under the 2025 Stock Incentive Plan.
When do Michael J. Higgins’ Voyager Therapeutics (VYGR) stock options expire?
The options expire on June 9, 2036, giving him over a decade to exercise them after vesting. After that expiration date, any unexercised options become worthless and no longer provide the right to buy Voyager Therapeutics common shares.
How many Voyager Therapeutics (VYGR) derivative securities does Michael J. Higgins hold after this Form 4 transaction?
Following this grant, he holds 30,000 stock options as reported in the filing. These represent rights to acquire Voyager Therapeutics common stock at 3.43 per share, subject to the vesting terms and the June 9, 2036 expiration date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates